Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats schizophrenia. ANDA 201824, held by Mylan. Clozapine.
As of Nov 15, 2026, ANDA 201824 (Clozapine), held by Mylan, was first approved by FDA on Sep 15, 2015, with 12 approved supplements and 0 published complete response letters.
First approved: Sep 15, 2015
Supplements approved: 12
Complete response letters: 0
What It's For
From the FDA-approved label (Indications and Usage)
Clozapine orally disintegrating tablets (Clozapine ODT) is an atypical antipsychotic indicated for: Treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, Clozapine ODT should be used only in patients who have failed to respond adequately to standard antipsychotic treatment Reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior 1.
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters